|
|
|
|
| LEADER |
03088nma a2200829 u 4500 |
| 001 |
EB001992581 |
| 003 |
EBX01000000000000001155483 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
210512 ||| eng |
| 020 |
|
|
|a books978-3-03943-554-8
|
| 020 |
|
|
|a 9783039435548
|
| 020 |
|
|
|a 9783039435531
|
| 100 |
1 |
|
|a Huang, Shile
|
| 245 |
0 |
0 |
|a mTOR Signaling in Metabolism and Cancer
|h Elektronische Ressource
|
| 260 |
|
|
|a Basel, Switzerland
|b MDPI - Multidisciplinary Digital Publishing Institute
|c 2020
|
| 300 |
|
|
|a 1 electronic resource (204 p.)
|
| 653 |
|
|
|a muscle
|
| 653 |
|
|
|a basal cell carcinoma
|
| 653 |
|
|
|a adhesion
|
| 653 |
|
|
|a cell metabolism
|
| 653 |
|
|
|a combination
|
| 653 |
|
|
|a Acute Lymphoblastic leukemia
|
| 653 |
|
|
|a inhibitors
|
| 653 |
|
|
|a cell signalling
|
| 653 |
|
|
|a tissue regeneration
|
| 653 |
|
|
|a integrins
|
| 653 |
|
|
|a Medicine / bicssc
|
| 653 |
|
|
|a histone deacetylase
|
| 653 |
|
|
|a synergy
|
| 653 |
|
|
|a everolimus
|
| 653 |
|
|
|a targeted therapies
|
| 653 |
|
|
|a tumor
|
| 653 |
|
|
|a clinical trials
|
| 653 |
|
|
|a photodynamic therapy
|
| 653 |
|
|
|a hematologic malignancies
|
| 653 |
|
|
|a Foxp3
|
| 653 |
|
|
|a neuron
|
| 653 |
|
|
|a Akt
|
| 653 |
|
|
|a mTOR signalling
|
| 653 |
|
|
|a cancers
|
| 653 |
|
|
|a mTOR
|
| 653 |
|
|
|a TNBC
|
| 653 |
|
|
|a PI3K/AKT/mTOR
|
| 653 |
|
|
|a prostate cancer
|
| 653 |
|
|
|a mutant genes
|
| 653 |
|
|
|a intestine
|
| 653 |
|
|
|a biomarkers
|
| 653 |
|
|
|a mTOR signaling
|
| 653 |
|
|
|a eribulin
|
| 653 |
|
|
|a skin cancers
|
| 653 |
|
|
|a melanoma
|
| 653 |
|
|
|a Merkel cell carcinoma
|
| 653 |
|
|
|a regulatory T cells
|
| 653 |
|
|
|a PI3K
|
| 653 |
|
|
|a squamous cell carcinoma
|
| 653 |
|
|
|a T cells
|
| 653 |
|
|
|a invasion
|
| 653 |
|
|
|a metabolism
|
| 653 |
|
|
|a head and neck cancer
|
| 653 |
|
|
|a targeted therapy
|
| 653 |
|
|
|a liver
|
| 653 |
|
|
|a phytochemicals
|
| 700 |
1 |
|
|a Huang, Shile
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b DOAB
|a Directory of Open Access Books
|
| 500 |
|
|
|a Creative Commons (cc), https://creativecommons.org/licenses/by/4.0/
|
| 024 |
8 |
|
|a 10.3390/books978-3-03943-554-8
|
| 856 |
4 |
0 |
|u https://www.mdpi.com/books/pdfview/book/3163
|7 0
|x Verlag
|3 Volltext
|
| 856 |
4 |
2 |
|u https://directory.doabooks.org/handle/20.500.12854/69370
|z DOAB: description of the publication
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a The mechanistic/mammalian target of rapamycin (mTOR), a serine/threonine kinase, is a central regulator for human physiological activity. Deregulated mTOR signaling is implicated in a variety of disorders, such as cancer, obesity, diabetes, and neurodegenerative diseases. The papers published in this Special Issue summarize the current understanding of the mTOR pathway and its role in the regulation of tissue regeneration, regulatory T cell differentiation and function, and different types of cancer including hematologic malignancies, skin, prostate, breast, and head and neck cancer. The findings highlight that targeting mTOR pathway is a promising strategy to fight against certain human diseases.
|